Analytical Validation of a 37-Gene Next-Generation Sequencing Panel for Myeloid Malignancies and Review of Initial...

Area of Science:

• Hematology
• Oncology
• Genetics

Background:

• Myeloid neoplasms are clonal disorders driven by genetic mutations, necessitating accurate mutational profiling for diagnosis, prognosis, and treatment.
• Next-generation sequencing (NGS) is crucial for characterizing genetic alterations in myeloid malignancies.
• The Archer VariantPlex Core Myeloid panel is a targeted NGS assay for evaluating these mutations.

Purpose of the Study:

• To analytically validate the Archer VariantPlex Core Myeloid panel for detecting genetic variants in myeloid neoplasms.
• To assess the panel's performance characteristics, including sensitivity, specificity, and reproducibility.
• To evaluate the panel's utility in clinical practice for diagnosing and classifying myeloid malignancies.

Main Methods:

• Analytical validation using 58 DNA specimens with known variants (87 single-nucleotide variants, 23 insertions/deletions).
• Performance assessment included depth of coverage, analytical sensitivity, specificity, reproducibility, and limit of detection.
• Retrospective analysis of 535 clinical specimens and review of diagnostic classifications using WHO and ICC guidelines.

Main Results:

• The Archer NGS panel demonstrated 100% analytical sensitivity and specificity for single-nucleotide variants and small insertions/deletions (≤21 bp).
• The panel achieved 100% reproducibility with a reportable limit of detection at 5%.
• Retrospective analysis of 535 specimens showed mutation frequencies and patterns consistent with published data.

Conclusions:

• The Archer VariantPlex Core Myeloid panel is a validated, accurate, and reproducible NGS tool for detecting clinically significant variants in myeloid neoplasms.
• The panel provides valuable molecular information supporting diagnosis, prognosis, and risk stratification according to international guidelines.
• This NGS approach enhances the characterization of myeloid malignancies, aiding clinical decision-making.